Chinese Journal of Pharmacovigilance ›› 2014, Vol. 11 ›› Issue (11): 641-644.

    Next Articles

Research of Extraction Process of Modified Xiongqiong Decoction Based on Material Basis and Effect of Anti-cerebral Ischemia

FENG Qun1,2, CHI Xue-jie3, ZHANG Ya-nan4, SUN Rong1   

  1. 1 Shandong academy of Chinese Medicine, Shandong Ji'nan 250014, China;
    2 Tianjin University of Traditional Chinese Medicine, Tianjin 300073, China;
    3 Weifang Traditional Chinese Hospital, Shandong Weifang 261041, China;
    4 Jining Institute for Drug Control, Shandong Jining 272000, China
  • Received:2014-07-30 Revised:2018-07-18 Online:2014-11-08 Published:2016-03-02

Abstract: Objective Extraction process of modified Xiongqiong decoction was researched and optimized on the basis of mice models of cerebral ischemia-reperfusion damages according to its material basis. Methods Six extraction processes of modified Xiongqiong decoction were explored according to modern references. Contents of active ingredients in the extracts were determined and protective effects of them on mice models of cerebral ischemia-reperfusion damages were observed. Optimum extraction process was selected according to determination of material basis and comparison of anti-cerebral ischemia. Results Active ingredients in the extract of the fifth extraction process is comprehensive relatively according to the integrated evaluation to volatile oil, walnut oil and ferulic acid. Extract of the fifth extraction process improved most obviously cerebral ischemia-reperfusion damages in all the extracts. Conclusion Model of "quality-efficacy" comprehensive assessment can guarantee effectiveness of Chinese medicine compound. The fifth extraction process has been confirmed to be optimum extraction process of modified Xiongqiong decoction preliminarily. However specific optimum parameters of the fifth extraction process need to be confirmed by a further study.

Key words: modified Xiongqiong decoction, cerebral ischemia-reperfusion damages, extraction process, determination

CLC Number: 

Copyright © Editorial office of Chinese Journal of Pharmacovigilance
Tel: 010-80990708 E-mail: ywjj@cdr-adr.org.cn